Hormonal
Pioglitazone, a thiazolidinedione, significantly reduces the risk of developing type 2 diabetes in patients with impaired glucose tolerance and stabilizes beta-cell function, with a favorable cardiovascular safety profile compared to rosiglitazone.
Pioglitazone is a powerful drug that can prevent diabetes and protect pancreatic beta-cells in people with prediabetes. It is more effective than metformin in some studies but can cause weight gain and fluid retention. It is generally reserved for cases where other treatments fail or are not suitable, due to its side effect profile.
Ежегодный уровень заболеваемости СД2 составил 2,1% в группе пиоглитазона и 7,6% – в группе плацебо... в отличие от росоглитазона, в исследовании TOSCA.IT было продемонстрировано, что пиоглитазон на протяжении 5 лет наблюдения не влиял на частоту сердечно-сосудистых исходов
Why this rating
Based on specific RCTs (Pioglitazone In Prevention Of Diabetes, TOSCA.IT) cited in the review.
Source
Modern aspects for preventive therapy of type 2 diabetes mellitus
В. В. Салухов et al. · Meditsinskiy sovet = Medical Council · 2019
DOI 10.21518/2079-701x-2019-4-6-13
More from this paper
- Metformin therapy reduces the risk of developing type 2 diabetes in patients with prediabetes, with the greatest preventive effect observed in individuals with higher baseline glycated hemoglobin (HbA1c) and a history of gestational diabetes.Good
- Acarbose, an alpha-glucosidase inhibitor, reduces the risk of developing type 2 diabetes in patients with impaired glucose tolerance, but its effectiveness is lower than that of lifestyle modification and metformin.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →